학술논문
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity
Document Type
Article
Author
Source
In Annals of Oncology December 2011 22(12):2646-2653
Subject
Language
ISSN
0923-7534